Pàgina inicial > Resultats de la cerca: John, T.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
11 p, 379.4 KB Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC / Wu, Yi-Long (Guangdong Lung Cancer Institute) ; John, Thomas (Austin Health) ; Grohe, Christian (Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (University of California) ; Kim, Sang-We (University of Ulsan) ; Kato, Terufumi (Kanagawa Cancer Center) ; Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ; Vu, Huu Vinh (Choray Hospital) ; Wang, Zhije (Chinese Academy of Medical Sciences) ; Lu, Shun (Shanghai Jiao Tong University) ; Lee, Kye Young (Konkuk University Medical Center) ; Akewanlop, Charuwan (Siriraj Hospital) ; Yu, Chong-Jen (National Taiwan University College of Medicine) ; de Marinis, Filippo (European Institute of Oncology) ; Bonanno, Laura (Istituto Oncologico Veneto) ; Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ; Shepherd, Frances A. (University of Toronto) ; Zeng, Lingmin (AstraZeneca) ; Atasoy, Ajlan (AstraZeneca) ; Herbst, Roy S. (Yale School of Medicine) ; Tsuboi, Masahiro (National Cancer Center Hospital East) ; Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 - 10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433  
Registre complet - Creative Commons
2.
11 p, 421.8 KB Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ; John, Thomas (Department of Medical Oncology. Austin Health) ; Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ; Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ; Kim, Sang-We (Department of Oncology. Asan Medical Center) ; Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ; Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ; Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ; Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ; Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ; Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ; Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ; Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ; Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ; Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ; Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ; Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296  
Registre complet - Creative Commons
3.
9 p, 1.3 MB A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer / Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences) ; Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; John, T. (Department of Medical Oncology. Austin Health) ; Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, J.W. (David Geffen School of Medicine. University of California) ; Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences) ; Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine) ; Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, H.V. (Department of Thoracic Surgery. Choray Hospital) ; Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center) ; Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS) ; Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto) ; Zeng, L. (Late Oncology Statistics. AstraZeneca) ; Hodge, R. (Late Oncology Statistics. AstraZeneca) ; Atasoy, A. (Late Oncology Research and Development. AstraZeneca) ; Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca) ; Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. [...]
2021 - 10.2217/fon-2021-0752
Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
2 John, Thomas
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem